SB274
To Restrict Wholesale Distributors Of Controlled Substances And Legend Drugs From Limiting Or Terminating Sales Of Controlled Substances To Certain Licensed Professionals; And To Declare An Emergency.
Last Action (May 1, 2023): Sine Die adjournment
Sponsors
AI-Generated Summary
Senate Bill 274 seeks to regulate how wholesale pharmaceutical distributors manage the distribution of controlled substances to pharmacies and licensed healthcare providers in Arkansas. The bill establishes strict requirements that wholesalers must follow before limiting or terminating the supply of controlled substances, including filing formal complaints with the relevant licensing boards based on specific data and allegations of aberrant behavior. It mandates that any such changes in distribution must involve oversight from the Arkansas State Board of Pharmacy and prohibits arbitrary service terminations. Wholesale distributors are required to provide 120 days' notice for voluntary terminations of service relationships. The bill also institutes penalties for non-compliance, including fines of at least $100,000 per violation and potential license revocation. Finally, the bill includes an emergency clause to ensure its provisions take effect immediately upon becoming law.
Potential Impact Analysis
Who Might Benefit?
The primary beneficiaries are pharmacies and licensed healthcare providers in Arkansas, as the bill protects them from sudden, potentially arbitrary interruptions in their supply chains for controlled substances. By establishing a formalized, transparent, and complaint-driven process for service termination, these entities gain greater operational stability and a regulatory mechanism to challenge wholesaler decisions.
Who Might Suffer?
The primary entities negatively impacted are wholesale pharmaceutical distributors, who face increased administrative burdens, strict reporting requirements to the Arkansas State Board of Pharmacy, and significant financial risk due to high minimum fines for non-compliance. These distributors may also face limitations in their ability to swiftly terminate business relationships with providers they deem high-risk or problematic, potentially hindering their compliance efforts regarding federal anti-diversion regulations.
Get Notified
Receive an email when this bill's status changes.